McKesson stock: Morgan Stanley raises target to USD 1,207

McKesson stock drew fresh analyst attention on Friday, October 30, after Morgan Stanley raised its price target and maintained an Overweight rating. Markets Insider, citing TipRanks, reported that analyst Erin Wright lifted the target to USD 1,207 from USD 977.

Morgan Stanley raises its target

The higher target marks a significant change in Morgan Stanley's published view. The report did not alter the Overweight stance, leaving the broker's assessment positive while investors await McKesson's next financial update.

At Lang & Schwarz, McKesson stock traded at 891.20 euros at 10:48:49 CET on Saturday, October 31. The quote was available without a verified Xetra closing basis, so no daily or weekly percentage comparison is stated.

Specialty care remains strategic

McKesson's broader expansion into specialty and home infusion services remains tied to its planned investment in Option Care Health. In an October 6 filing, McKesson, Clayton Dubilier & Rice and Option Care Health said they had agreed on a transaction with an enterprise value of approximately USD 5.8 billion. McKesson is to invest approximately USD 1.4 billion for a minority interest of about 49%, while CD&R would hold the majority.

The transaction is expected to close in the first half of calendar 2027, subject to shareholder and regulatory approvals, according to the SEC filing. Option Care Health is expected to remain a separate business under its existing management.

Investors can follow the real-time quote of McKesson stock for subsequent trading updates.

The broader US market can be followed through the S&P 500.

More news and analyses are available on McKesson stock.